Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more) Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Amarin Corporation plc AMRN

Healthcare Biotechnology
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult... see more

Recent & Breaking News (NDAQ:AMRN)

Amarin Highlights New Evidence of Therapeutic Value of EPA in Reducing Cardiovascular Events in At-Risk Patients Presented at ACC.23/WCC

GlobeNewswire March 6, 2023

Amarin Announces New REDUCE-IT® Data at ACC.23/WCC Showing Benefit of VASCEPA®/VAZKEPA® (Icosapent Ethyl) in High-Risk Patients with a Recent Acute Coronary Syndrome Event

GlobeNewswire March 5, 2023

Amarin Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

GlobeNewswire March 1, 2023

Sarissa Capital Wins Proxy Contest Against Amarin by Huge Landslide

Business Wire February 28, 2023

Amarin Announces Preliminary Voting Results Following 2023 General Meeting of Shareholders

GlobeNewswire February 28, 2023

Amarin and CSL Seqirus Announce Exclusive License and Distribution Agreement to Commercialize VAZKEPA® (Icosapent Ethyl) in Australia and New Zealand

GlobeNewswire February 28, 2023

Amarin Sets the Record Straight on Sarissa's Latest Misstatements

GlobeNewswire February 27, 2023

Amarin Corporation to Present New Data Evaluating VASCEPA®/VAZKEPA® (Icosapent Ethyl) at ACC.23/WCC

GlobeNewswire February 27, 2023

Sarissa Capital Condemns Amarin Board for Frontrunning Results of Proxy Contest With Egregious Equity Grants to Executives

Business Wire February 27, 2023

Amarin to Present at Cowen's 43rd Annual Health Care Conference

GlobeNewswire February 22, 2023

Sarissa Capital Reminds Amarin Shareholders Today Is the Last Day to Vote "FOR" Change

Business Wire February 21, 2023

Amarin to Report Fourth Quarter and Full Year 2022 Financial Results And Host Conference Call on March 1st, 2023

GlobeNewswire February 21, 2023

Sarissa Capital Urges Amarin Shareholders to Vote "FOR" Necessary Change

Business Wire February 20, 2023

Amarin Urges Shareholders to Vote "Against" Sarissa's Harmful Proposals at Upcoming General Meeting - IT HAS NO PLAN, NO NEW IDEAS AND AN UNDERQUALIFIED SLATE

GlobeNewswire February 17, 2023

Sarissa Capital Urges Amarin Shareholders to Vote for Change and Remake Amarin for Shareholders

Business Wire February 17, 2023

Sarissa Capital Blasts Amarin's Repeated False Statements; Clearly Amarin Will Say Anything to Keep Sarissa Off the Board

Business Wire February 16, 2023

Leading Independent Proxy Firm ISS Joins Glass Lewis in Recommending that Amarin Shareholders Vote "AGAINST" Sarissa's Value-Destructive Proposals

GlobeNewswire February 16, 2023

Amarin Clearly and Definitively Instructed Registrar to Accept ALL Submitted Proxy Cards

GlobeNewswire February 16, 2023

Sarissa Capital Uncovers That Amarin's Registrar Had Not Been Instructed to Accept Blue Proxy Cards Even Though Legally Required to Do So

Business Wire February 15, 2023

Sarissa Capital Disappointed That Amarin Webcast Continues Board's Defense of Poor Results and Lack of Accountability

Business Wire February 14, 2023